Lv1
66 积分 2023-07-11 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
14小时前
待确认
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
4天前
已完结
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer
10天前
已完结
Spatial transcriptomics reveals clonal relationships between intraductal carcinoma and adjacent invasive prostate cancer
21天前
已完结
[18F]RCCB6 PET/CT in Diagnosing Clear Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging
30天前
已完结
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
1个月前
已完结
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and Adolescents
1个月前
已完结
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
1个月前
已完结
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
1个月前
已完结
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer
1个月前
已关闭
皖公网安备34019202002308
